

Impactful Polygenic Methylation Genetic Polymorphisms

MTHFR SNP, limits Methylfolate production.
*Methylfolate, B2/FAD, B3/NAD

85%

BHMT SNP, limits Betaine production.
*Betaine, Zinc

29%

**JCP, 05/16, 330 Patients MDD/MTHFR SNP
8 Week Monotherapy Study
EnLyte Group (159) 42% Remission, .93 ES
Placebo Group (123) 1.8% Remission
Side Effects = Placebo
Only MTHFR Study in the Literature**

DAO SNP, Breaks down Histamine improving ADHD symptoms.
*All Ingredients

79%

MTHFD1 SNP, limits Folinic acid production.
*Folinic Acid, B2/FAD, Zinc

50%

HNMT SNP, Inactivation of Histamine.
*All Ingredients

15%

DHFR SNP, limits production of all folates downstream.
*Methylfolate, Folinic Acid

28%

COMT SNP, regulates Dopamine levels in prefrontal cortex.
*All Ingredients

25%

SHMT SNP, limits 5,10 Methylene THF production.
*Methylfolate, B6/P5P

37%

TCN1/2 SNP, reduces B12 transport intracellularly.
*B12/ADSYL, B6/P5P, Methylfolate

44%

MTR SNP, limits Methionine Synthase production.
*All Ingredients

33%

AHCY SNP, regulates SAH to Homocysteine conversion.
*All Ingredients

25%

MAO-A SNP, regulates Neurotransmitter breakdown.
*B2/FAD, B3/NAD, Magnesium, Iron

40%

APOE4 SNP, increases brain inflammation.
*PS Omega 3s, Methylfolate, B6/P5P, B12/ADSYL

20%

“The broad-spectrum B vitamin coenzymes, mineral cofactors, and phospholipid omega 3 ingredients in EnLyte were specifically designed to empirically manage and mitigate all 13 methylation polymorphisms for normal and balanced methylation outcomes, which correlate with proven clinical outcomes in ADHD and Major Depressive Disorder as mono or adjunctive therapy.” — Towny Robinson, Inventor of EnLyte

*EnLyte Ingredient Remedy